Zymeworks Daiichi I-O deal could potentially be worth USD 485 million
Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million. The new agreement will grant the Japanese pharma two more licenses for an upfront technology access fee of USD 18 million as per the reports.
Celsius grabs USD 65 million funding to develop precision drugs for cancer, autoimmune disease
Celsius Therapeutics is all set to develop single-cell genomic sequencing based therapeutics. After bagging USD 65 million in series A funding, the venture will now sequence defined patient samples for identifying the individual cells responsible for disease. Company is hoping to bring forth the first ever precision medicines for curing the autoimmune disease.
MeiraGTx files for USD 86 million IPO
MeiraGTx, a gene therapy based startup has filed for USD 86 million IPO to push some of its gene therapies into the clinical trials. Company is initially targeting inherited retinal diseases with therapies that are designed to stop/pause vision loss.
EIP Pharma bags USD 20.5 million in series B funding to push Alzheimer’s drug through phase 2
EIP Pharma has recently bagged USD 20.5 million in series B funding to support the Alzheimer’s treatment, neflamapimod that is currently in the phase 2b of development. The funding will also help in building up its team and support the search of other CNS disorders for which the drug might be useful.